ID   HSC 536
AC   CVCL_G045
SY   HSC-536; HSC536; GM13020
DR   CLO; CLO_0013992
DR   BioSample; SAMN00802014
DR   Coriell; GM13020
DR   Wikidata; Q54896372
RX   PubMed=7994019;
RX   PubMed=14754601;
CC   Sequence variation: Mutation; HGNC; HGNC:3584; FANCC; Simple; p.Leu554Pro (c.1661T>C); ClinVar=VCV000012043; Zygosity=Unspecified (Coriell=GM13020).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C125704; Fanconi anemia, complementation group C
DI   ORDO; Orphanet_84; Fanconi anemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   5Y
CA   Transformed cell line
DT   Created: 11-02-13; Last updated: 19-12-24; Version: 14
//
RX   PubMed=7994019; DOI=10.1182/blood.V84.12.3995.bloodjournal84123995;
RA   Liu J.M., Buchwald M., Walsh C.E., Young N.S.;
RT   "Fanconi anemia and novel strategies for therapy.";
RL   Blood 84:3995-4007(1994).
//
RX   PubMed=14754601;
RA   Clarke A.A., Gibson F.M., Scott J., Myatt N.E., Rutherford T.R.;
RT   "Fanconi's anemia cell lines show distinct mechanisms of cell death in
RT   response to mitomycin C or agonistic anti-Fas antibodies.";
RL   Haematologica 89:11-20(2004).
//